Management of Acute Kidney Injury in Cirrhosis with Ascites
Immediate Diagnostic Approach
The first priority is to rapidly distinguish hepatorenal syndrome-AKI (HRS-AKI) from other causes of AKI, because HRS-AKI requires immediate vasoconstrictor therapy with terlipressin (or norepinephrine) plus albumin, whereas other AKI etiologies demand different interventions. 1
Establish the Diagnosis of HRS-AKI
Diagnostic criteria: Cirrhosis with ascites, serum creatinine ≥1.5 mg/dL, no improvement after volume expansion with albumin (1 g/kg up to 100 g), absence of shock, no recent nephrotoxic drug exposure, and absence of parenchymal kidney disease on urinalysis and ultrasound. 1
Laboratory pattern: Look for prerenal markers—urine sodium <10 mEq/L, fractional excretion of sodium (FENa) <0.3%, bland urinary sediment without cellular casts, proteinuria <500 mg/day, and <50 RBCs per high-power field. 1
Imaging: Renal ultrasound must show no hydronephrosis, no portal vein thrombosis, and normal kidney size to exclude obstruction and structural disease. 1
Rapid progression: Serum creatinine doubling in <2 weeks (e.g., 1.0 to 2.4 mg/dL) despite intervention strongly suggests Type 1 HRS-AKI and carries a poor prognosis. 1
Rule Out Alternative AKI Etiologies
Prerenal azotemia: Responds to albumin-based volume resuscitation (1 g/kg up to 100 g); if creatinine improves, this is not HRS-AKI. 2, 3
Acute tubular necrosis (ATN): Suggested by muddy brown casts, FENa >1%, and recent hypotension or nephrotoxin exposure; managed with supportive care and withdrawal of offending agents. 2
Acute interstitial nephritis (AIN): Look for eosinophiluria, white blood cell casts, and recent drug exposure (NSAIDs, antibiotics); may require corticosteroids after stopping the offending drug. 2
Abdominal compartment syndrome: Measure bladder pressure if tense ascites is present; abdominal perfusion pressure (APP) <60 mmHg predicts AKI and requires urgent large-volume paracentesis. 2, 4
Infection-related AKI: Screen for spontaneous bacterial peritonitis (ascitic fluid neutrophil count >250/mm³) and other infections, which are present in 25% of decompensated cirrhosis cases and drive AKI through endotoxemia and inflammatory cytokines (IL-6, TNF-α). 5
First-Line Treatment for HRS-AKI: Terlipressin + Albumin
Once HRS-AKI is diagnosed, immediately initiate terlipressin 1 mg IV bolus every 4–6 hours via peripheral line (no central access required) combined with albumin 1 g/kg IV on day 1 (maximum 100 g), then 20–40 g/day until treatment completion. 6
Dosing Protocol
Initial regimen: Terlipressin 1 mg IV every 4–6 hours (total 4–6 mg/day) through a peripheral IV line without dilution. 6
Albumin co-administration is mandatory: Terlipressin alone achieves only a 25% response rate versus 77% when combined with albumin. 6
Dose escalation: If serum creatinine has not decreased by ≥25–30% by day 3–4, increase terlipressin to 2 mg IV every 4–6 hours (maximum 12 mg/day). 6
Alternative continuous infusion: Start terlipressin at 2 mg/day as continuous IV infusion, which provides equal efficacy with fewer ischemic side effects compared to bolus dosing. 6
Treatment duration: Continue for up to 14 days or until serum creatinine falls to ≤1.5 mg/dL, then discontinue 24 hours after reaching target. 6
Predictors of Response
Favorable factors: Baseline bilirubin <10 mg/dL, baseline creatinine <5 mg/dL, and mean arterial pressure (MAP) increase ≥5–10 mmHg by day 3. 6
Contraindications: Baseline creatinine >5 mg/dL (unlikely to benefit), SpO₂ <90% on room air or supplemental oxygen, and active coronary/mesenteric/peripheral ischemia. 6
Safety Monitoring
Ischemic complications: Occur in ~12% of patients (abdominal pain, chest pain, digital ischemia, arrhythmias); permanently discontinue terlipressin if any ischemic symptoms develop. 6
Respiratory failure: Develops in 14–30% of patients, especially those with acute-on-chronic liver failure (ACLF) grade 3 or baseline hypoxemia; these patients require ICU monitoring. 6
Ward vs. ICU: Patients with ACLF grade <3 can be safely managed on a regular ward with vital signs and pulse oximetry every 2–4 hours; ACLF grade 3 (≥3 organ failures) requires ICU admission. 6
Albumin caution: Excessive volume expansion increases respiratory failure risk (11% vs. 2% placebo); reassess albumin need after 1–2 days based on volume status using point-of-care ultrasound. 6
Second-Line Treatment: Norepinephrine + Albumin
If terlipressin is unavailable, contraindicated, or fails to produce a ≥25% creatinine reduction by day 3–4, switch to norepinephrine 0.5 mg/hour (≈5 µg/min) continuous IV infusion, titrating up to 3 mg/hour (≈10 µg/min) to achieve MAP increase >10 mmHg above baseline. 6
Efficacy: Norepinephrine produces comparable response rates (39–70%) to terlipressin in non-responders. 6
Albumin co-administration: Continue albumin 20–40 g/day IV as with terlipressin. 6
Superiority of terlipressin in ACLF: In acute-on-chronic liver failure, terlipressin demonstrates clear superiority over norepinephrine (day 4 response 26.1% vs. 11.7%, p=0.03; 28-day survival 48.3% vs. 20%, p=0.001). 6
Management of Non-HRS-AKI Etiologies
Prerenal Azotemia
Volume resuscitation: Administer albumin 1 g/kg IV (maximum 100 g) and reassess creatinine after 48 hours; improvement confirms prerenal AKI. 2, 3
Avoid nephrotoxins: Discontinue NSAIDs, aminoglycosides, and contrast agents; hold diuretics temporarily. 3, 7
Optimize cardiac output: Maximize effective arterial blood volume by treating infection, avoiding excessive diuresis, and maintaining MAP >65 mmHg. 3
Acute Tubular Necrosis
Supportive care: Withdraw nephrotoxic agents, maintain euvolemia, and avoid further renal insults. 2
Monitor for recovery: ATN typically resolves over 7–14 days with supportive management. 2
Abdominal Compartment Syndrome
Large-volume paracentesis: Remove ascitic fluid (≥5 liters) with albumin replacement (8 g per liter removed) to relieve intra-abdominal hypertension and improve renal perfusion. 2, 4
Target APP >60 mmHg: Persistently low abdominal perfusion pressure (APP = MAP minus intra-abdominal pressure) is an independent risk factor for acute renal failure. 4
Infection-Related AKI
Early antibiotic therapy: Treat spontaneous bacterial peritonitis with third-generation cephalosporins (ceftriaxone 2 g IV daily) and administer albumin 1.5 g/kg on day 1 and 1 g/kg on day 3 to prevent HRS-AKI. 5
Screen for bacterial translocation: Infection is present in 25% of decompensated cirrhosis cases and 35–40% of ACLF cases; pathogen-associated molecular patterns activate inflammatory cascades that worsen hemodynamics and directly injure renal parenchyma. 5
Outpatient AKI Recognition and Prevention
Ambulatory AKI (A-AKI) occurs in 12% of cirrhosis patients, is under-recognized in 42% of cases, and carries a 12% 90-day mortality; high-risk patients (ascites, MELD-Na >15, hepatocellular carcinoma, alcohol-associated liver disease) require close outpatient monitoring of serum creatinine. 7
Key Precipitants of A-AKI
Hypovolemia: Excessive diuresis and gastrointestinal losses (diarrhea, vomiting) are the most common triggers. 7
Nephrotoxin exposure: NSAIDs, aminoglycosides, and contrast agents frequently precipitate A-AKI. 7
Infection: Urinary tract infections, spontaneous bacterial peritonitis, and pneumonia drive 25% of A-AKI cases. 5, 7
Prevention Strategies
Avoid aggressive diuresis: Limit furosemide to 40–80 mg/day and spironolactone to 100–200 mg/day; monitor weight loss to <0.5 kg/day in patients without peripheral edema. 3
Albumin for large-volume paracentesis: Administer 8 g albumin per liter of ascites removed (≥5 liters) to prevent post-paracentesis circulatory dysfunction. 2
Early infection detection: Obtain diagnostic paracentesis for any clinical deterioration (fever, abdominal pain, encephalopathy, renal dysfunction) to rule out spontaneous bacterial peritonitis. 5
Prognosis and Transplant Evaluation
One-year survival: Patients who achieve HRS-AKI reversal with vasoconstrictor therapy have approximately 65% one-year survival. 6
Urgent transplant evaluation: Liver transplantation is the definitive treatment for HRS-AKI; all patients should be urgently evaluated for transplant candidacy. 1
Post-transplant outcomes: Achieving a response to vasoconstrictor therapy is associated with improved post-transplant outcomes. 6
Common Pitfalls to Avoid
Do not delay vasoconstrictor therapy: Once HRS-AKI is diagnosed, immediate initiation of terlipressin (or norepinephrine) plus albumin is critical; delays worsen outcomes. 1, 8
Do not use albumin alone for established HRS-AKI: Albumin monotherapy is insufficient once HRS-AKI develops; lack of response to albumin is a diagnostic criterion. 1
Do not continue the same terlipressin dose beyond day 3–4 without escalation: If creatinine reduction is <25–30%, escalate to 2 mg every 4–6 hours (maximum 12 mg/day). 6
Do not overlook infection: Screen for spontaneous bacterial peritonitis and other infections in every AKI case, as infection is present in 25% of decompensated cirrhosis and drives AKI through endotoxemia and inflammatory cytokines. 5
Do not ignore abdominal perfusion pressure: In patients with tense ascites, measure bladder pressure and calculate APP (MAP minus intra-abdominal pressure); APP <60 mmHg predicts AKI and requires urgent large-volume paracentesis. 4
Do not miss ambulatory AKI: Outpatients with ascites, MELD-Na >15, hepatocellular carcinoma, or alcohol-associated liver disease require frequent creatinine monitoring, as 42% of A-AKI events are unrecognized. 7